AFINITOR vs SORAFENIB TOSYLATE

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate

Possible drug interaction. AFINITOR and SORAFENIB TOSYLATE are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	AFINITOR	SORAFENIB TOSYLATE
Rating	70/100	New
Pharmacy pays	~$229.16 /30	—
Type	RX	RX
Active ingredient	EVEROLIMUS	SORAFENIB TOSYLATE
Manufacturer	Novartis	Yabao Pharm
Dosage forms	Tablet	Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	None
Half-life	about 30 hours (mean terminal elimination half-life)	—
Treats	—	Renal Cell Carcinoma, Hepatocellular Carcinoma, Thyroid Neoplasms

afinitor sorafenib tosylate

Rating

70/100

New

Pharmacy pays

~$229.16 /30

—

Type

Active ingredient

EVEROLIMUS

SORAFENIB TOSYLATE

Manufacturer

Novartis

Yabao Pharm

Dosage forms

Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Half-life

about 30 hours (mean terminal elimination half-life)

—

Treats

—

Renal Cell Carcinoma, Hepatocellular Carcinoma, Thyroid Neoplasms

Frequently asked questions

What is the difference between Afinitor and Sorafenib Tosylate?

Afinitor contains Everolimus, while Sorafenib Tosylate contains Sorafenib Tosylate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.